| Abstrakt: |
A recent study conducted at Schneider Children's Medical Center in Petah Tikva, Israel, examined the outcomes of children with ataxia-telangiectasia (A-T) and hematological malignancies. The study included 202 patients from 25 countries and found that the four-year overall survival and event-free survival rates were 50.8% and 47.9%, respectively. The study also found that the absence of ATM kinase activity, a protein involved in DNA repair, was associated with decreased survival rates and increased treatment-related mortality. The researchers suggest that tailored treatment approaches based on ATM kinase activity could improve outcomes for these patients. [Extracted from the article] |
